Financial Summary for Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Performance Overview

Consolidated revenue for the fiscal year ending March 2026 reached JPY 2,139.2 billion (up 11.9% YoY), driven by expanded sales of key strategic products PADCEV, IZERVAY, VYLOY, VEOZAH, and XTANDI. Operating income rose significantly to JPY 382.6 billion (up 832.4% YoY), while net income attributable to owners of parent also increased sharply to JPY 291.5 billion (up 474.5% YoY). On a core basis, operating income was JPY 555.7 billion (up 41.6% YoY) and core net income was JPY 424.4 billion (up 43.5% YoY), demonstrating improved profitability. Research and development expenses were controlled at JPY 314.8 billion (down 3.9% YoY).

Financial Position and Dividends

At the end of the fiscal year ending March 2026, total assets amounted to JPY 3,567.0 billion (an increase of JPY 227.5 billion from the previous term), total equity reached JPY 1,830.9 billion (up JPY 317.6 billion), and the equity ratio attributable to owners of parent rose to 51.3%. The annual dividend was set at JPY 78 (including a year-end dividend of JPY 39), marking an increase of JPY 4 from the previous term. Earnings guidance for the fiscal year ending March 2027 anticipates consolidated revenue of JPY 2,220.0 billion (up 3.8% YoY), core operating income of JPY 620.0 billion (up 11.6% YoY), core net income of JPY 460.0 billion (up 8.4% YoY), and an annual dividend of JPY 80 (interim JPY 40, year-end JPY 40).